Magrolimab is a first-in-class investigational monoclonal antibody against CD47 and macrophage checkpoint inhibitor, which interferes with the recognition of CD47 by the SIRPα receptor on macrophages, thus blocking the “don’t eat me” signal used by cancer cells to evade phagocytosis (Figure 1). Here, CD47 is linked to cancer.